We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
The Zacks Analyst Blog Highlights Meta Platforms, Netflix, Pfizer, SIFCO Industries and Altigen Communications
Read MoreHide Full Article
For Immediate Release
Chicago, IL – February 27, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Meta Platforms, Inc. (META - Free Report) , Netflix, Inc. (NFLX - Free Report) , Pfizer Inc. (PFE - Free Report) , SIFCO Industries, Inc. (SIF - Free Report) and Altigen Communications, Inc. (ATGN - Free Report) .
Here are highlights from Thursday’s Analyst Blog:
Top Research Reports for Meta, Netflix and Pfizer
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Meta Platforms, Inc., Netflix, Inc. and Pfizer Inc., as well as two micro-cap stocks SIFCO Industries, Inc. and Altigen Communications, Inc.. The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.
These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
The daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens, attempting to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.
Shares of Meta have declined -12.5% over the past six months against the Zacks Internet - Software industry's decline of -21.2%. The company is benefiting from increasing AI-infusion across its services, which currently reach more than 3.58 billion people daily. META's improved recommendation system is driving up user engagement. Instagram Reels had a strong fourth-quarter, with watch time up more than 30% year-over-year in the United States.
Facebook video time continued to grow double-digits year-over-year in the United States. Recommendation improvement drove 20% lift in time spent on Threads. AI usage is making META a popular name among advertisers.
Meta Platforms now expects to invest significantly more over the next few years in developing more advanced models and the largest AI services in the world. However, monetization of these AI services will take considerable time, which is a concern. Increasing regulatory challenges is a headwind for investors.
Netflix's shares have underperformed the Zacks Broadcast Radio and Television industry over the past six months (-32% vs. -20.5%). The company's primary concerns persist around the proposed Warner Bros Discovery acquisition facing regulatory hurdles and market skepticism. Elevated debt levels and content obligations pose leverage risks. While 2026 guidance projects revenue growth of 12-14%, intensifying competition from Disney and Amazon may pressure subscriber growth rates going forward.
Nevertheless, Netflix is benefiting from its growing subscriber base, thanks to a robust localized and foreign-language content portfolio and healthy engagement levels with about two hours of viewing per member per day, indicating strong member retention.
NFLX has set an ambitious target to double its revenues by 2030 and reach a $1 trillion market capitalization, supported by a diversified content strategy, including international programming, live events, and gaming initiatives.
Shares of Pfizer have gained +11.3% over the past six months against the Zacks Large Cap Pharmaceuticals industry's gain of +24.4%. The company's stock has taken a beating for the past three years as its revenues have declined substantially due to lower sales of its COVID products.
Pfizer also faces some other challenges, like U.S. Medicare Part D headwinds and the upcoming LOE cliff in the 2026-2030 period as several of its key products, including Eliquis, Vyndaqel, Ibrance, Xeljanz and Xtandi, face patent expirations.
However, Pfizer's non-COVID operational revenues are improving, driven by its key products like Vyndaqel, Padcev and Eliquis, new launches and newly acquired products which should partially offset the LOE impact over the next several years. Pfizer expects its recently launched and acquired products and a strong pipeline to help revive top-line growth toward the end of the decade.
SIFCO's shares have outperformed the Zacks Aerospace - Defense Equipment industry over the past six months (+104.7% vs. +17.6%). This microcap company with a market capitalization of $88.07 million is positioned in structurally resilient aerospace and defense markets, benefiting from long-cycle platforms, high qualification barriers and growing military/rotorcraft demand.
Recent results reflect improved throughput, pricing discipline and exit of lower-margin work, driving a meaningful margin rebound and stronger operating leverage. A solid backlog underpins revenue visibility, and deleveraging has improved financial flexibility.
However, earnings durability depends on sustained volumes and a favorable mix. Risks include defense concentration, working-capital swings, input-cost inflation, contract execution complexity and regulatory exposure. The current valuation suggests investors remain cautious, pricing in execution risk and cyclicality, while leaving meaningful upside if margin gains and cash flow prove sustainable.
Shares of Altigen Communications have underperformed the Zacks Communication - Components industry over the past six months (-28.7% vs. +176.7%). This microcap company with a market capitalization of $11.90 million is facing a revenue decline Y/Y, driven by a weaker hosted services mix, and customer concentration increased materially, with the top five accounts representing 83% of sales.
Elevated churn tied to platform transitions, a higher receivables reserve, and capitalized software impairment risk add execution uncertainty. Nevertheless, Altigen held $2.6 million in cash and nearly $2.9 million in working capital as of Dec. 31, 2025, with minimal leverage, supporting operational resilience.
Gross margins remain strong, and lower operating and R&D expenses enhance operating leverage, positioning earnings to benefit from incremental revenue gains. Recent partnerships expand distribution without materially increasing fixed costs, while rising deferred revenue improves forward visibility.
Free: Instant Access to Zacks' Market-Crushing Strategies
Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.
Today you can tap into those powerful strategies – and the high-potential stocks they uncover – free. No strings attached.
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
The Zacks Analyst Blog Highlights Meta Platforms, Netflix, Pfizer, SIFCO Industries and Altigen Communications
For Immediate Release
Chicago, IL – February 27, 2026 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Meta Platforms, Inc. (META - Free Report) , Netflix, Inc. (NFLX - Free Report) , Pfizer Inc. (PFE - Free Report) , SIFCO Industries, Inc. (SIF - Free Report) and Altigen Communications, Inc. (ATGN - Free Report) .
Here are highlights from Thursday’s Analyst Blog:
Top Research Reports for Meta, Netflix and Pfizer
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Meta Platforms, Inc., Netflix, Inc. and Pfizer Inc., as well as two micro-cap stocks SIFCO Industries, Inc. and Altigen Communications, Inc.. The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.
These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today's research reports here >>>
Ahead of Wall Street
The daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens, attempting to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.
You can read today's AWS here >>> NVIDIA Slam Dunks on Earnings Once Again
Today's Featured Research Reports
Shares of Meta have declined -12.5% over the past six months against the Zacks Internet - Software industry's decline of -21.2%. The company is benefiting from increasing AI-infusion across its services, which currently reach more than 3.58 billion people daily. META's improved recommendation system is driving up user engagement. Instagram Reels had a strong fourth-quarter, with watch time up more than 30% year-over-year in the United States.
Facebook video time continued to grow double-digits year-over-year in the United States. Recommendation improvement drove 20% lift in time spent on Threads. AI usage is making META a popular name among advertisers.
Meta Platforms now expects to invest significantly more over the next few years in developing more advanced models and the largest AI services in the world. However, monetization of these AI services will take considerable time, which is a concern. Increasing regulatory challenges is a headwind for investors.
(You can read the full research report on Meta here >>>)
Netflix's shares have underperformed the Zacks Broadcast Radio and Television industry over the past six months (-32% vs. -20.5%). The company's primary concerns persist around the proposed Warner Bros Discovery acquisition facing regulatory hurdles and market skepticism. Elevated debt levels and content obligations pose leverage risks. While 2026 guidance projects revenue growth of 12-14%, intensifying competition from Disney and Amazon may pressure subscriber growth rates going forward.
Nevertheless, Netflix is benefiting from its growing subscriber base, thanks to a robust localized and foreign-language content portfolio and healthy engagement levels with about two hours of viewing per member per day, indicating strong member retention.
NFLX has set an ambitious target to double its revenues by 2030 and reach a $1 trillion market capitalization, supported by a diversified content strategy, including international programming, live events, and gaming initiatives.
(You can read the full research report on Netflix here >>>)
Shares of Pfizer have gained +11.3% over the past six months against the Zacks Large Cap Pharmaceuticals industry's gain of +24.4%. The company's stock has taken a beating for the past three years as its revenues have declined substantially due to lower sales of its COVID products.
Pfizer also faces some other challenges, like U.S. Medicare Part D headwinds and the upcoming LOE cliff in the 2026-2030 period as several of its key products, including Eliquis, Vyndaqel, Ibrance, Xeljanz and Xtandi, face patent expirations.
However, Pfizer's non-COVID operational revenues are improving, driven by its key products like Vyndaqel, Padcev and Eliquis, new launches and newly acquired products which should partially offset the LOE impact over the next several years. Pfizer expects its recently launched and acquired products and a strong pipeline to help revive top-line growth toward the end of the decade.
(You can read the full research report on Pfizer here >>>)
SIFCO's shares have outperformed the Zacks Aerospace - Defense Equipment industry over the past six months (+104.7% vs. +17.6%). This microcap company with a market capitalization of $88.07 million is positioned in structurally resilient aerospace and defense markets, benefiting from long-cycle platforms, high qualification barriers and growing military/rotorcraft demand.
Recent results reflect improved throughput, pricing discipline and exit of lower-margin work, driving a meaningful margin rebound and stronger operating leverage. A solid backlog underpins revenue visibility, and deleveraging has improved financial flexibility.
However, earnings durability depends on sustained volumes and a favorable mix. Risks include defense concentration, working-capital swings, input-cost inflation, contract execution complexity and regulatory exposure. The current valuation suggests investors remain cautious, pricing in execution risk and cyclicality, while leaving meaningful upside if margin gains and cash flow prove sustainable.
(You can read the full research report on SIFCO here >>>)
Shares of Altigen Communications have underperformed the Zacks Communication - Components industry over the past six months (-28.7% vs. +176.7%). This microcap company with a market capitalization of $11.90 million is facing a revenue decline Y/Y, driven by a weaker hosted services mix, and customer concentration increased materially, with the top five accounts representing 83% of sales.
Elevated churn tied to platform transitions, a higher receivables reserve, and capitalized software impairment risk add execution uncertainty. Nevertheless, Altigen held $2.6 million in cash and nearly $2.9 million in working capital as of Dec. 31, 2025, with minimal leverage, supporting operational resilience.
Gross margins remain strong, and lower operating and R&D expenses enhance operating leverage, positioning earnings to benefit from incremental revenue gains. Recent partnerships expand distribution without materially increasing fixed costs, while rising deferred revenue improves forward visibility.
(You can read the full research report on Altigen Communications here >>>)
Free: Instant Access to Zacks' Market-Crushing Strategies
Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.
Today you can tap into those powerful strategies – and the high-potential stocks they uncover – free. No strings attached.
Get all the details here >>
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.